- \n
- \nGE HealthCare\u2019s Revolution Vibe CTi<\/sup> enables more facilities to elevate patient care by offering advanced cardiac imaging technology that helps deliver fast, accurate diagnoses, improve operational efficiency, and enhance patient outcomes.\n<\/li>\n
- \nCardiovascular disease (CVD) is the leading cause of death and healthcare costs worldwide,ii<\/sup> with research projecting it could cause over 23 million deaths by 2030.iii<\/sup> The average number of cardiac computed tomography (CT) procedures performed per site is expected to increase 175 percent,iv<\/sup> highlighting its value as a first-line imaging tool for diagnosis, treatment planning, and post-treatment follow-up.\n<\/li>\n<\/ul>\n
CHICAGO–(BUSINESS WIRE<\/a>)–
\nAt the American College of Cardiology 2025 meeting, GE HealthCare (Nasdaq: GEHC) will proudly introduce Revolution\u2122 Vibe,i<\/sup> a new computed tomography (CT) system with Unlimited One-Beat Cardiac imaging to deliver consistent, high-quality images for patients, even in challenging cases like atrial fibrillation and heavily calcified coronaries. Combined with the company\u2019s impressive ECG-less Cardiac, TrueFidelity DL, SnapShot Freeze 2, and Effortless Workflow’s AI-powered solutions, Revolution Vibe enables fast, accurate diagnoses, a more comfortable patient experience, and more efficient workflows.v<\/sup><\/p>\n\nAs cardiovascular disease (CVD) continues to rise globally,vi<\/sup> the need for advanced diagnostic technologies like cardiac CT angiography (CCTA) becomes increasingly critical. CCTA offers a non-invasive, cost-effective, and highly sensitive method for diagnosing coronary artery disease (CAD), making it a valuable tool for clinicians. The National Institute for Health and Care Excellence (NICE) recommends CCTA as the first-line investigation for patients with chest pain due to suspected CAD, highlighting its importance in improving diagnostic certainty. vii<\/sup> Similarly, recent increases in Medicare reimbursement rates for CCTA are a positive step towards making this technology more accessible.\n<\/p>\n
\n“Expanding access to CCTA is crucial for managing the rising prevalence of CVD, ensuring timely and accurate diagnoses for a larger patient population,\u201d shares Jean-Luc Procaccini, President and CEO, Molecular Imaging and Computed Tomography, GE HealthCare. \u201cOur introduction of Revolution Vibe underscores our commitment to this mission. The system is designed to encourage the broader adoption of and access to cardiac imaging, combining advanced technology with AI-powered solutions to deliver fast, accurate diagnoses and a more comfortable patient experience. It is designed to empower healthcare providers to offer the highest quality care, even in the most challenging cases.”\n<\/p>\n
\nFor CCTA to be truly effective, the CT system must be designed to address the most difficult cardiac exams, including irregularities in heart rhythms, patients with limited cooperation, and those with calcification, stents or bypasses. These complications challenge cardiologists and radiologists alike, often leading to repeat scans, inaccurate diagnoses, heightened patient risk and dissatisfaction, and increased costs.viii, ix, x, xi, xii, xiii, xiv, xv<\/sup><\/p>\n
\nGE HealthCare designed Revolution Vibe to address these challenges. The \u2018all in one\u2019 system provides advanced cardiac CT solutions to help make CCTA more accessible to more facilities and patients, while also enabling greater diagnostic confidence, patient comfort, and workflow efficiency.\n<\/p>\n
\n“Revolution Vibe has significantly enhanced our cardiac imaging capabilities, doubling our CCTA capacity while reducing scan times and improving image quality,\u201d shares Dr. Christopher Ahlers, Radiologist and Managing Partner at Radiomed. \u201cThe advanced technology streamlines workflows, reduces reliance on invasive diagnostics, and ensures high-quality care for all patients, including those with challenging conditions. By adopting Revolution Vibe, we have improved operational efficiency, increased diagnostic confidence, and elevated patient satisfaction, positioning us at the forefront of cardiac care.”\n<\/p>\n
\nRevolution Vibe enhances cardiac capabilities, enabling Unlimited One-Beat Cardiac<\/b>imaging. This advanced technology offers clear, full-heart images at low dose, improving access for patients with complex conditions like atrial fibrillation, breath-holding difficulties, heavily calcified coronaries, in-stent restenosis, and cases without an ECG trace. TrueFidelity DL images for cardiac<\/b> and SnapShot Freeze 2<\/b> offer Revolution Vibe users impressive image quality with motion free images. The system also offers ECG-less Cardiac<\/b> to help improve patient access and simplify preparation for exams without an ECG connection, making it ideal for situations where speed is a priority or when the ECG signal is unavailable.\n<\/p>\n
Effortless Cardiac Workflow<\/b> also optimizes the system for cardiac scans, leveraging AI to automatically select protocols and position the patient \u2013 optimizing scanning time and making it easy to use for every user, even junior or inexperienced technologists. In a clinical evaluation, the one-step decision tree workflow helped reduce exam time by 50 percent, freeing up four minutes of radiologists\u2019 time per study.xvi<\/sup> It also helped reduce the patient preparation process by up to five minutes per scan.xvi<\/sup> Much of this time is saved due to reduced positioning time, minimized usage of beta blockers, and eliminating the need for an ECG connection when the cardiac exam needs to be prioritized for patient access and speed.\n<\/p>\n
\nFinally, Revolution Vibe is designed to help healthcare facilities expand their service lines and manage lifecycle costs effectively, driving topline growth. With the growing need for cardiac CT, the system\u2019s versatility and ability to handle increased cardiac exams and general imaging needs make it accessible to more facilities.\n<\/p>\n
\nBeyond initial costs, Revolution Vibe offers energy-efficient design, extensive training, fleet management, and Smart Subscription, ensuring facilities stay updated with the latest technology. This innovative technology maximizes operational efficiency, enhances staff expertise, and delivers better patient outcomes, making it a wise long-term investment.\n<\/p>\n
\nFor more information on Revolution Vibe, please visit gehealthcare.com<\/a>. Those attending the American College of Cardiology (ACC) 2025 meeting in Chicago are also invited to experience the system\u2019s formal unveiling in GE HealthCare\u2019s booth (#9013) on Saturday, March 29 at 10:30 a.m.\n<\/p>\n
About GE HealthCare Technologies Inc.<\/b><\/p>\n
\nGE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient\u2019s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.\n<\/p>\n
\nGE HealthCare is proud to be among 2025 Fortune World\u2019s Most Admired Companies\u2122<\/a>.\n<\/p>\n
\nFollow us on LinkedIn<\/a>, X<\/a>, Facebook<\/a>, Instagram<\/a>, and Insights<\/a> for the latest news, or visit our website https:\/\/www.gehealthcare.com<\/a> for more information.\n<\/p>\n
i<\/sup> Revolution Vibe is CE marked and 510(k) pending with the U.S. FDA. Not available for sale in the United States or all regions.\n<\/p>\n
ii<\/sup> Shapiro MD et al. Eur J Radiol. 2008;66(1):37\u201341. doi:10.1016\/j.ejrad.2007.05.006.\n<\/p>\n
iii<\/sup> Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. (2012) 380:2095\u2013128. 10.1016\/S0140-6736(12)61728-0. https:\/\/pubmed.ncbi.nlm.nih.gov\/23245604\/<\/a><\/p>\n
iv<\/sup> IMV. 2023 CT Market Outlook Report (p. 45).\n<\/p>\n
v<\/sup> Walter, M. (2024, November 8). \u201ca huge win\u201d: CMS significantly increases Medicare payments for cardiac CT. Cardiovascular Business. https:\/\/cardiovascularbusiness.com\/topics\/cardiac-imaging\/cms-increases-medicare-payments-cardiac-ct-ccta<\/a>.\n<\/p>\n
vi<\/sup> World Health Organization. Cardiovascular diseases (CVDs). June 11, 2021. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds)<\/a>. Accessed February 2023\n<\/p>\n
vii<\/sup> Moss AJ et al. The Updated NICE Guidelines: Cardiac CT as the First-Line Test for Coronary Artery Disease. Curr Cardiovasc Imaging Rep (2017) 10: 15.\n<\/p>\n
viii<\/sup> Shapiro MD et al. EurJ Radiol. 2008;66(1):37\u201341.\n<\/p>\n
ix<\/sup> Pannu HK et al. J Comput Assist Tomogr. 2008 Mar-Apr;32(2):247-51.\n<\/p>\n
x<\/sup> Graaf D et al. American Journal of Cardiology. 2010;105(6):767\u2013772.\n<\/p>\n
xi<\/sup> Techasith T et al. J Cardiovasc Comput Tomogr. 2011;5(4):255\u2013263.\n<\/p>\n
xii<\/sup> Ghoshhajra BB et al. Am J Med. 2012;125(8):764\u2013772.\n<\/p>\n
xiii<\/sup> Hamid S et al. Am J Emerg Med. 2010;28(4):494\u2013498.\n<\/p>\n
xiv<\/sup> Cotarlan V et al. Am J Cardiol. 2013;111(5):661\u2013666.\n<\/p>\n
xv<\/sup> Hoffmann U et al. Am Heart J. 2012;163(3):330-338.\n<\/p>\n
xvi<\/sup> GE HealthCare case study. \u201cRevolution Vibe: A new vision for heart at Radiomed.\u201d\n<\/p>\n
<\/p>\n
View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250328986429\/en\/<\/a><\/span><\/p>\n
GE HealthCare Media Contact:
\n<\/b>
Margaret Steinhafel
\n
M +1 608 381 8829
\n
margaret.steinhafel@gehealthcare.com<\/a><\/p>\nKEYWORDS:<\/b> United States North America Illinois<\/p>\n
INDUSTRY KEYWORDS:<\/b> Technology Medical Devices Cardiology Software Biotechnology Radiology Health Science Artificial Intelligence Other Science<\/p>\n
- \nCardiovascular disease (CVD) is the leading cause of death and healthcare costs worldwide,ii<\/sup> with research projecting it could cause over 23 million deaths by 2030.iii<\/sup> The average number of cardiac computed tomography (CT) procedures performed per site is expected to increase 175 percent,iv<\/sup> highlighting its value as a first-line imaging tool for diagnosis, treatment planning, and post-treatment follow-up.\n<\/li>\n<\/ul>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20250328986429\/en\/1907724\/3\/GE_HealthCare_logo_NEW_March_2023.jpg\"){kind=logo}
<\/td>\n<\/tr>\n